1. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27 Kip1 .
- Author
-
Chen Y, Du M, Yusuying S, Liu W, Tan Y, and Xie P
- Subjects
- Apoptosis, Biomarkers, Tumor, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Cycle, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27 genetics, Enzyme Inhibitors pharmacology, Female, Humans, NEDD8 Protein genetics, Prognosis, Survival Rate, Tumor Cells, Cultured, Ubiquitin-Activating Enzymes genetics, Ubiquitin-Activating Enzymes metabolism, Breast Neoplasms drug therapy, Cyclin-Dependent Kinase Inhibitor p27 metabolism, Cyclopentanes pharmacology, Gene Expression Regulation, Neoplastic drug effects, MicroRNAs genetics, NEDD8 Protein metabolism, Pyrimidines pharmacology, Ubiquitin-Activating Enzymes antagonists & inhibitors
- Abstract
MLN4924/Pevonedistat, a Nedd8-activating enzyme (NAE, E1) inhibitor, has shown notable anti-cancer effect in pre-clinical trials, but it still faces tolerance resistance risk. Combination target therapy indicates a much better clinical effect than single target, and miRNAs are beneficial for easy detection in bodily fluids and tissues. Up to now, MLN4924 and miRNA-targeting combination approaching to treat breast cancer patients remains largely unknown. Here, microRNA-seq analysis showed that the expression of miR-1303 was significantly decreased after MLN4924 treatment in breast cancer cells. Moreover, miR-1303 was abnormally high in breast cancer tissues, and breast cancer patients with high miR-1303 showed poor prognosis. Functionally, excessive miR-1303 promoted the malignant phenotypes of breast cancer cells. Excessive miR-1303 accelerated cell cycle progression by promoting G2/M arrest. Furthermore, we revealed that miR-1303 targeted p27
Kip1 to release G2/M arrest. Notably, excessive miR-1303 partially disturbed the anti-cancer effect of MLN4924. These findings provide potential evidences for combined anti-cancer target therapy of breast cancer patients in the future., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF